Patient already on corticosteroid therapy for an unrelated indication, Patient with impending death or respiratory failure necessitating ICU care within 24 hours including inability to maintain SpO2 â?¥90% despite HFNC with flow 60 L/min and FiO2 1.0 or ,if available, NIV with PEEP of upto 8 cm H2O and FiO2 1.0, Patients who have received â?¥2 day of steroids outside hospital care or within the hospital outside of wards that are involved in the study. These doses must be no greater than 12 mg dexamethasone or 64 mg methylprednisolone cumulatively, Patients with a known contraindication to corticosteroids including untreated bacterial sepsis, diabetic keto-acidosis, and invasive fungal infections such as mucormycosis, medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial, Pregnancy, Recruitment in another therapeutic trial, Use of immunosuppressive drugs, cytotoxic chemotherapy in the past 21 days, Neutropenia due to hematological or solid malignancies with bone marrow invasion, Refusal of consent. <br/ >

Patient already on corticosteroid therapy for an unrelated indication, Patient with impending death or respiratory failure necessitating ICU care within 24 hours including inability to maintain SpO2 â?¥90% despite HFNC with flow 60 L/min and FiO2 1.0 or ,if available, NIV with PEEP of upto 8 cm H2O and FiO2 1.0, Patients who have received â?¥2 day of steroids outside hospital care or within the hospital outside of wards that are involved in the study. These doses must be no greater than 12 mg dexamethasone or 64 mg methylprednisolone cumulatively, Patients with a known contraindication to corticosteroids including untreated bacterial sepsis, diabetic keto-acidosis, and invasive fungal infections such as mucormycosis, medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial, Pregnancy, Recruitment in another therapeutic trial, Use of immunosuppressive drugs, cytotoxic chemotherapy in the past 21 days, Neutropenia due to hematological or solid malignancies with bone marrow invasion, Refusal of consent. <br/ >

N/A

N/A

Patient already on corticosteroid therapy for an unrelated indication, Patient with impending death or respiratory failure necessitating ICU care within 24 hours including inability to maintain SpO2 â?¥90% despite HFNC with flow 60 L/min and FiO2 1.0 or ,if available, NIV with PEEP of upto 8 cm H2O and FiO2 1.0, Patients who have received â?¥2 day of steroids outside hospital care or within the hospital outside of wards that are involved in the study. These doses must be no greater than 12 mg dexamethasone or 64 mg methylprednisolone cumulatively, Patients with a known contraindication to corticosteroids including untreated bacterial sepsis, diabetic keto-acidosis, and invasive fungal infections such as mucormycosis, medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial, Pregnancy, Recruitment in another therapeutic trial, Use of immunosuppressive drugs, cytotoxic chemotherapy in the past 21 days, Neutropenia due to hematological or solid malignancies with bone marrow invasion, Refusal of consent. <br/ >

Patient already on corticosteroid therapy for an unrelated indication, Patient with impending death or respiratory failure necessitating ICU care within 24 hours including inability to maintain SpO2 â?¥90% despite HFNC with flow 60 L/min and FiO2 1.0 or ,if available, NIV with PEEP of upto 8 cm H2O and FiO2 1.0, Patients who have received â?¥2 day of steroids outside hospital care or within the hospital outside of wards that are involved in the study. These doses must be no greater than 12 mg dexamethasone or 64 mg methylprednisolone cumulatively, Patients with a known contraindication to corticosteroids including untreated bacterial sepsis, diabetic keto-acidosis, and invasive fungal infections such as mucormycosis, medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial, Pregnancy, Recruitment in another therapeutic trial, Use of immunosuppressive drugs, cytotoxic chemotherapy in the past 21 days, Neutropenia due to hematological or solid malignancies with bone marrow invasion, Refusal of consent. <br/ >